These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 7337747)

  • 21. Thyroid-stimulating hormone and prolactin levels in breast cancer.
    Aldinger KA; Schultz PN; Blumenschein GR; Samaan NA
    Arch Intern Med; 1978 Nov; 138(11):1638-41. PubMed ID: 102267
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship between PRL levels and steroid receptors in breast cancer.
    Marugo M; Fazzuoli L; Bernasconi D; Berta S; Giordano G
    Anticancer Res; 1988; 8(4):819-23. PubMed ID: 3178171
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reproducibility of plasma steroid hormones, prolactin, and insulin-like growth factor levels among premenopausal women over a 2- to 3-year period.
    Missmer SA; Spiegelman D; Bertone-Johnson ER; Barbieri RL; Pollak MN; Hankinson SE
    Cancer Epidemiol Biomarkers Prev; 2006 May; 15(5):972-8. PubMed ID: 16702379
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential release of prolactin variants in postpartum and early follicular phase women.
    Liu JH; Lee DW; Markoff E
    J Clin Endocrinol Metab; 1990 Sep; 71(3):605-10. PubMed ID: 2118537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Longitudinal evaluation of the luteal phase and its transition into the follicular phase.
    Vermesh M; Kletzky OA
    J Clin Endocrinol Metab; 1987 Oct; 65(4):653-8. PubMed ID: 3116029
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Can plasma prolactin predict tamoxifen resistance in patients with advanced breast cancer?
    Bhatavdekar JM; Patel DD; Karelia NH; Shah NG; Ghosh N; Vora HH; Suthar TP; Balar DB; Doctor SS
    Eur J Surg Oncol; 1994 Apr; 20(2):118-21. PubMed ID: 8181575
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A potential role of endogenous progesterone in modulation of GH, prolactin and thyrotrophin secretion during normal menstrual cycle.
    Caufriez A; Leproult R; L'Hermite-Balériaux M; Moreno-Reyes R; Copinschi G
    Clin Endocrinol (Oxf); 2009 Oct; 71(4):535-42. PubMed ID: 19222493
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abnormalities in evening plasma prolactin levels in nulliparous women with benign or malignant breast disease.
    Tarquini A; di Martino L; Malloci A; Kwa HG; van der Gugten AA; Bulbrook RD; Wang DY
    Int J Cancer; 1978 Dec; 22(6):687-90. PubMed ID: 721323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma concentrations of C-19 steroids, estrogens, FSH, LH and prolactin in post-menopausal women with an without breast cancer.
    Bird CE; Cook S; Owen S; Sterns EE; Clark AF
    Oncology; 1981; 38(6):365-8. PubMed ID: 6795556
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bromocriptine therapy of luteal insufficiency accompanied with hyperprolactinemia in the follicular phase.
    Kano T; Nishikawa K
    Nihon Sanka Fujinka Gakkai Zasshi; 1983 Jul; 35(7):975-80. PubMed ID: 6875348
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endocrine aspects of benign breast disease.
    Parlati E; Liberale I; Travaglini A; Morelli P; Menini E; Dell'Acqua S
    Cancer Detect Prev; 1992; 16(1):25-6. PubMed ID: 1312904
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The relationship of plasma prolactin to 17-B oestradiol in women with tumours of the breast.
    Jones MK; Ramsay ID; Collins WP; Dyer GI
    Eur J Cancer (1965); 1977 Oct; 13(10):1109-12. PubMed ID: 923610
    [No Abstract]   [Full Text] [Related]  

  • 33. Prolactin as a local growth promoter in patients with breast cancer: GCRI experience.
    Bhatavdekar JM; Patel DD; Shah NG; Vora HH; Suthar TP; Ghosh N; Chikhlikar PR; Trivedi TI
    Eur J Surg Oncol; 2000 Sep; 26(6):540-7. PubMed ID: 11034803
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Permanent alterations induced in plasma prolactin and estrogen receptor concentration in benign and malignant tissue of women who started oral contraceptive use at an early age.
    Olsson H; Lindahl B; Ranstam J; Borg A; Fernö M; Norgren A
    Anticancer Res; 1987; 7(4B):853-6. PubMed ID: 3674773
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Correlation between serum prolactin secretion patterns and the ability of fertilization and cleavage of human oocyte (effects of transient hyperprolactinemia on fertilization and cleavage of human oocyte)].
    Azuma K; Yamano S
    Nihon Sanka Fujinka Gakkai Zasshi; 1985 Oct; 37(10):2097-106. PubMed ID: 4078410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effect of serum prolactin on cycle stimulation and fertilization of human oocytes].
    Reinthaller A; Deutinger J; Csaicsich P; Riss P; Müller-Tyl E; Fischl F; Janisch H
    Geburtshilfe Frauenheilkd; 1987 Apr; 47(4):246-8. PubMed ID: 3109998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma prolactin concentrations and risk of postmenopausal breast cancer.
    Tworoger SS; Eliassen AH; Rosner B; Sluss P; Hankinson SE
    Cancer Res; 2004 Sep; 64(18):6814-9. PubMed ID: 15375001
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prolactin response to dopamine and valproate administration in breast cancer patients.
    Stalldecker GB; Pigni J; Fuentes AM; Vegh I
    Biomed Pharmacother; 1989; 43(4):301-6. PubMed ID: 2506942
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HER2 expression in breast cancer: correlation with endocrine function and psychological status in operable and metastatic breast cancer.
    Lissoni P; Messina G; Rovelli F; Brivio F; Fumagalli L; Villa S; Bartolacelli E
    In Vivo; 2009; 23(6):987-9. PubMed ID: 20023245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pulsatile secretion of prolactin during the human menstrual cycle].
    Masaoka K; Kitazawa M; Niibe T; Kumasaka T
    Nihon Sanka Fujinka Gakkai Zasshi; 1988 Dec; 40(12):1793-9. PubMed ID: 3209907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.